Submit Manuscript  

Article Details

Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer’s Treatment


Bijo Mathew*   Pages 1 - 5 ( 5 )


Background: Multi-functional design of ligands emerged as new drug design paradigm of Alzheimer’s disease (AD). Given the complexity of AD, the molecules showing dual inhibition of monoamine oxidase (MAO) and acetylcho- linesterase (AChE) with neuroprotective properties could prevent the progressive neural degeneration effectively.

Materials and methods: Numerous studies documented that chalcone is a privileged structural framework for the inhibition of both MAO and AChE.

Results: The recent studies suggested that the development of chalcone candidates endowed with pharmacophores of FDA approved drugs may become an active molecules in the field of current AD research.

Conclusion: The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD.


Chalcones, pharmacophore, monoamine oxidase, acetylcholinesterase, flurbiprofen, rivastigmine.


Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, 678557, Kerala

Read Full-Text article